Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SpaceX Shares Surge as Wall Street Backs AI Growth Potential 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
ASX Faces Legal Action Over Failed Blockchain CHESS Project 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Airbus Joins Air India A320 Altitude Drop Probe 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
US Judge Dismisses Gautam Adani Criminal Charges 
Samsung, SK Hynix Shares Surge on Report of Potential Temasek Investment 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
ADNOC Gas Targets Up to $4B Profit in 2026 
OpenAI Executive Brad Lightcap to Leave for New AI Venture 
Add as a preferred source on Google
Roche is buying Genmark Diagnostics for $1.8 billion or €1.5 billion, and this was revealed on Monday, March 15. The price is for the full acquisition of the US-based molecular diagnostic tests maker.
The numbers in Roche’s newest investment
Roche’s price offer is equivalent to the price of $24.05 per share in an all-cash deal. This also showed a premium of 43% on GenMark’s closing stock on Feb. 10, just before the speculations about Roche’s plans to purchase GenMark made rounds, as per CNBC.
The Swiss pharmaceuticals manufacturer company decided to buy the leading provider of multiplex molecular diagnostic solutions so it can expand the business and make its presence in the diagnostics sector.
“Acquiring GenMark Diagnostics will broaden our molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against infectious diseases,” Thomas Schinecker, Roche’s chief executive officer, said via press release.
It was added that the acquisition that was approved by the respective board of directors of Roche and GenMark Diagnostics is expected to be completed within the second quarter of 2021. Once the negotiations are done, the latter’s main operations will not be moved but will continue in its current office location in Carlsbad, California.
The setup in the merger deal
The terms in the merger agreement were partly disclosed, and one clause states that Roche will immediately and directly initiate a tender offer to purchase all outstanding stocks of GenMark’s shares.
At any rate, GenMark’s portfolio will complement and further enhance Roche’s molecular diagnostics portfolio. It is also expected that the Swiss company will widen its global network reach when it starts to distribute GenMark’s items and products.
“As a part of Roche, we can accelerate our mission to enable rapid diagnosis of infectious disease to improve patient outcomes,” CEO of GenMark Diagnostics, Scott Mendel, said. “Together with Roche’s diagnostics healthcare solutions, we will be able to provide a full suite of molecular diagnostic solutions to customers around the world.”
Finally, Mendel added that GenMark is thrilled to become part of the globally known Roche. He is confident that they made the right decision to move forward with the Swiss firm.
